JCR Pharmaceuticals Co., Ltd.
4552.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | ¥12,793,000 | ¥8,569,000 | ¥7,192,000 | ¥9,223,000 |
| % Growth | 49.3% | 19.1% | -22% | – |
| Cost of Goods Sold | ¥2,005,000 | ¥2,395,000 | ¥4,374,000 | ¥2,677,000 |
| Gross Profit | ¥10,788,000 | ¥6,174,000 | ¥2,818,000 | ¥6,546,000 |
| % Margin | 84.3% | 72.1% | 39.2% | 71% |
| R&D Expenses | ¥4,487,000 | ¥3,348,000 | ¥5,506,000 | ¥3,349,000 |
| G&A Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| SG&A Expenses | ¥3,354,000 | ¥3,470,000 | ¥3,256,000 | ¥3,212,000 |
| Sales & Mktg Exp. | ¥0 | ¥0 | ¥0 | ¥0 |
| Other Operating Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| Operating Expenses | ¥7,841,000 | ¥6,818,000 | ¥8,762,000 | ¥6,561,000 |
| Operating Income | ¥2,947,000 | -¥644,000 | -¥5,944,000 | -¥60,000 |
| % Margin | 23% | -7.5% | -82.6% | -0.7% |
| Other Income/Exp. Net | ¥345,000 | -¥107,000 | -¥153,000 | ¥253,000 |
| Pre-Tax Income | ¥3,292,000 | -¥751,000 | -¥6,097,000 | ¥238,000 |
| Tax Expense | ¥1,013,000 | -¥180,000 | -¥1,879,000 | ¥36,000 |
| Net Income | ¥2,256,000 | -¥546,000 | -¥4,183,000 | ¥115,000 |
| % Margin | 17.6% | -6.4% | -58.2% | 1.2% |
| EPS | 18.51 | -4.48 | -33.8 | 0.93 |
| % Growth | 513.2% | 86.7% | -3,734.4% | – |
| EPS Diluted | 18.5 | -4.48 | -33.8 | 0.94 |
| Weighted Avg Shares Out | 121,888 | 121,845 | 123,744 | 123,245 |
| Weighted Avg Shares Out Dil | 121,942 | 121,845 | 123,744 | 121,825 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥29,000 | ¥9,000 | ¥22,000 | ¥23,000 |
| Interest Expense | ¥78,000 | ¥79,000 | ¥52,000 | ¥40,000 |
| Depreciation & Amortization | ¥721,000 | ¥738,000 | ¥868,000 | ¥799,250 |
| EBITDA | ¥4,088,000 | ¥67,000 | -¥5,179,000 | ¥739,250 |
| % Margin | 32% | 0.8% | -72% | 8% |